Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter
Rhea-AI Summary
Ping An Biomedical (Nasdaq: PASW) received a Nasdaq Minimum Bid Price Deficiency Letter after its closing bid price failed to meet the $1.00 minimum for the period Oct 10, 2025–Nov 20, 2025. Nasdaq provided an 180-calendar-day compliance period ending May 25, 2026 to regain compliance.
If not cured, the company may be eligible for an additional 180 days only if it meets market value and other initial listing standards (except bid price) and files intent to cure; otherwise Nasdaq may issue a delisting notice. The company is evaluating options, including a possible reverse stock split, but cannot assure successful compliance.
Positive
- Nasdaq granted a 180-day compliance period until May 25, 2026
- Potential additional 180-day cure window if other listing standards met
Negative
- Closing bid price below $1.00 for Oct 10–Nov 20, 2025
- Risk of Nasdaq delisting if deficiency is not cured
- Possible reverse stock split may be required to regain compliance
- No assurance company will regain compliance within the period
News Market Reaction
On the day this news was published, PASW declined 3.59%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $362K from the company's valuation, bringing the market cap to $10M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peer stocks or sector momentum data were detected, indicating the Nasdaq bid-price deficiency letter is a company-specific catalyst for PASW rather than part of a broader sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 28 | Nasdaq compliance notice | Negative | -3.6% | Nasdaq minimum bid price deficiency letter and risk of potential delisting. |
Available history shows this Nasdaq compliance issue drew a negative price reaction, consistent with the adverse nature of a bid-price deficiency notice.
Recent news for PASW centers on Nasdaq compliance. On Nov 28, 2025, the company disclosed receipt of a Nasdaq Minimum Bid Price Deficiency Letter after its bid stayed below $1.00 from Oct 10–Nov 20, 2025. Nasdaq granted an initial 180-day compliance window ending May 25, 2026, with potential for another 180 days if other standards are met. The stock fell about -3.59% following this announcement, highlighting sensitivity to listing-risk news.
Market Pulse Summary
This announcement detailed Nasdaq’s notice that PASW failed to meet the $1.00 minimum bid price requirement, triggering an initial 180-day compliance period ending May 25, 2026, with potential for an additional 180 days if other standards are satisfied. The company indicated it might consider tools such as a reverse stock split. Investors should monitor any formal plans to cure the deficiency and future disclosures on Nasdaq listing status.
Key Terms
Nasdaq Listing Rules 5550(a)(2) regulatory
reverse stock split financial
forward-looking statements regulatory
prospectus regulatory
Nasdaq Capital Market regulatory
AI-generated analysis. Not financial advice.
Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter.
On November 24, 2025, Ping An Biomedical Co., Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from October 10, 2025 to November 20, 2025, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of
Nasdaq has provided the Company with an 180 calendar days compliance period, or until May 25, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.
The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
ABOUT PING AN BIOMEDICAL CO., LTD.
Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the trading of its Ordinary Shares or the closing of the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contacts
Ping An Biomedical Co., Ltd. Investor Relations Contact:
Building 13, No. 1 Headquarters, No. 5 Kechuang 2nd Street, Tongzhou District, Beijing
Tel : +8618910841158
Email: liupijun2025@163.com
FAQ
What did Ping An Biomedical (PASW) receive from Nasdaq on Nov 24, 2025?
How long does PASW have to regain Nasdaq compliance?
Can PASW get more time to cure the Nasdaq deficiency?
What actions might PASW take to regain Nasdaq compliance?
What happens if PASW does not regain compliance by May 25, 2026?
